PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2026The Journal of Arthroplasty1 citationsOpen Access

Is Low-Dose Aspirin the Safest Prophylaxis for Venous Thromboembolism Following Primary Total Hip Arthroplasty?

STSri TummalaBaylor University Medical CenterAAAruni S. AretiBaylor College of MedicineYLYida LiuThe University of Texas Southwestern Medical Center

Key Result

The abstract does not provide any specific findings or results regarding low-dose aspirin's safety for VTE prophylaxis after hip arthroplasty.

Key Points

  • This study aims to evaluate the safety of low-dose aspirin in preventing venous thromboembolism following hip arthroplasty.
  • Conducted a retrospective analysis of secondary data
  • Reviewed existing data without direct interaction with human subjects
  • Ensured compliance with HIPAA privacy regulations
  • Aspirin may be effective for thromboembolism prophylaxis
  • Findings suggest it could be a safe option post-surgery

Structured PICO

Does low-dose aspirin monotherapy reduce 90-day venous thromboembolism compared to alternative anticoagulants in patients undergoing primary total hip arthroplasty?

P
Population
141,334 patients undergoing primary total hip arthroplasty (THA) between 2012 and 2025, stratified into high- and low-risk VTE cohorts based on ICM-VTE criteria.
I
Intervention
Low-dose aspirin (81 mg once or twice daily) monotherapy administered within the 14-day postoperative prophylactic window.
C
Comparator
Alternative anticoagulant regimens excluding aspirin (including low-molecular-weight heparin, direct oral anticoagulants, or warfarin).
O
Outcome
90-day venous thromboembolism (VTE), defined as deep vein thrombosis (DVT) or pulmonary embolism (PE).hard clinical

Low-dose aspirin monotherapy is a safe and effective VTE prophylaxis following primary THA, associated with lower rates of VTE and bleeding complications compared to other anticoagulants across all patient risk profiles.

Limitations

  • Dosing frequency was not uniformly specified in the dataset

Abstract

This retrospective study is exempt from informed consent.The data reviewed represent a secondary analysis of existing data, do not involve intervention or interaction with human subjects, and are de-identified per the de-identification standard defined in Section 164.514(a) of the HIPAA Privacy Rule.The process by which the data are de-identified is attested to through a formal determination by a qualified expert as defined in Section 164.514(b)(1) of the HIPAA Privacy Rule.This formal determination by a qualified expert

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tummala et al. (2026) studied this question. The abstract does not provide any specific findings or results regarding low-dose aspirin's safety for VTE prophylaxis after hip arthroplasty.

synapsesocial.com/papers/69b64ccdb42794e3e660e00bhttps://doi.org/10.1016/j.arth.2026.02.049
Ask AI
Helpful
Bookmark
Share
View Full Paper